Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Edgewise Therapeutics (EWTX) PT Raised to $52 at Leerink
June 16, 2026 1:08 PM EDTLeerink analyst Joseph Schwartz raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $50.00) while maintaining a Outperform rating.
The analyst comments "We continue to think that CIRRUS Part D checks the key boxes for EDG-7500 across obstructive (oHCM) and non-obstructive... More
